Literature DB >> 27902679

Stem cells: Stemming the tide.

Asher Mullard.   

Abstract

Mesh：

Year:  2016        PMID： 27902679     DOI： 10.1038/540S11a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

Review 1.  Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - YES.

Authors:  Mark Freedman; Harold L Atkins
Journal:  Mult Scler       Date:  2016-07-21       Impact factor: 6.312

2.  Remyelination researchers regroup after proof-of-concept setback in multiple sclerosis.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2016-07-29       Impact factor: 84.694

Review 3.  Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases.

Authors:  Antonio Uccelli; Alice Laroni; Mark S Freedman
Journal:  Lancet Neurol       Date:  2011-07       Impact factor: 44.182

4.  Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.

Authors:  Harold L Atkins; Marjorie Bowman; David Allan; Grizel Anstee; Douglas L Arnold; Amit Bar-Or; Isabelle Bence-Bruckler; Paul Birch; Christopher Bredeson; Jacqueline Chen; Dean Fergusson; Mike Halpenny; Linda Hamelin; Lothar Huebsch; Brian Hutton; Pierre Laneuville; Yves Lapierre; Hyunwoo Lee; Lisa Martin; Sheryl McDiarmid; Paul O'Connor; Timothy Ramsay; Mitchell Sabloff; Lisa Walker; Mark S Freedman
Journal:  Lancet       Date:  2016-06-09       Impact factor: 79.321

5.  Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.

Authors:  Peter Connick; Madhan Kolappan; Charles Crawley; Daniel J Webber; Rickie Patani; Andrew W Michell; Ming-Qing Du; Shi-Lu Luan; Daniel R Altmann; Alan J Thompson; Alastair Compston; Michael A Scott; David H Miller; Siddharthan Chandran
Journal:  Lancet Neurol       Date:  2012-01-10       Impact factor: 44.182

6.  A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.

Authors:  R Saccardi; M S Freedman; M P Sormani; H Atkins; D Farge; L M Griffith; G Kraft; G L Mancardi; R Nash; M Pasquini; R Martin; P A Muraro
Journal:  Mult Scler       Date:  2012-03-01       Impact factor: 6.312
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.